Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Gilead Sciences
Deal Size : $35.0 million
Deal Type : Collaboration
Gilead and Genesis Partner To Develop Novel Therapies
Details : Gilead Sciences and Genesis Therapeutics entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Gilead Sciences
Deal Size : $35.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Andreessen Horowitz
Deal Size : $200.0 million
Deal Type : Series B Financing
Genesis Therapeutics Closes Oversubscribed $200 Million Series B
Details : The funds will be used to advance Genesis’ pipeline of AI-enabled programs, including its proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 21, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Andreessen Horowitz
Deal Size : $200.0 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $670.0 million
Deal Type : Collaboration
Details : The collaboration will deploy Genesis’ pioneering AI drug discovery platform, which combines 3D structure-aware deep neural networks with cutting-edge molecular simulation.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : $20.0 million
May 03, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $670.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?